Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis.

Xiaodan Qin | Liang Lin | Li Cao | Xinwei Zhang | Xiao Song | Jie Hao | Yan Zhang | Risheng Wei | Xiaojun Huang | Jin Lu | Qing Ge
Scientific reports | 2017

Reelin is an extracellular matrix protein that is crucial for neuron migration, adhesion, and positioning. We examined the expression of Reelin in a large cohort of multiple myeloma patients recorded in Gene Expression Omnibus (GEO) database and used over-expression and siRNA knockdown of Reelin to investigate the role of Reelin in myeloma cell growth. We find that Reelin expression is negatively associated with myeloma prognosis. Reelin promotes myeloma cell proliferation in vitro as well as in vivo. The Warburg effect, evidenced by increased glucose uptake and lactate production, is also enhanced in Reelin-expressing cells. The activation of FAK/Syk/Akt/mTOR and STAT3 pathways contributes to Reelin-induced cancer cell growth and metabolic reprogramming. Our findings further reveal that activated Akt and STAT3 pathways induce the upregulation of HIF1α and its downstream targets (LDHA and PDK1), leading to increased glycolysis in myeloma cells. Together, our results demonstrate the critical contributions of Reelin to myeloma growth and metabolism. It presents an opportunity for myeloma therapeutic intervention by inhibiting Reelin and its signaling pathways.

Pubmed ID: 28345605

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


GE Healthcare (tool)

RRID:SCR_000004

A commercial antibody supplier and provider of various services.

View all literature mentions

NCI-H929 (tool)

RRID:CVCL_1600

Cell line NCI-H929 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

U266B1 (tool)

RRID:CVCL_0566

Cell line U266B1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H929 (tool)

RRID:CVCL_1600

Cell line NCI-H929 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions